14Jan 2024
Continuous intrafemoral artery infusion of urokinase improves diabetic foot ulcers

Continuous intrafemoral artery infusion of urokinase improves diabetic foot ulcers

This single-center, randomized, parallel study investigates the impact of long-term intrafemoral artery infusion of low-dose urokinase therapy on diabetic foot ulcers (DFUs) and cardiovascular events. The trial involves 195 patients with DFUs, with the continuous intrafemoral thrombolysis group receiving intrafemoral urokinase for 7 days. Compared to conventional therapy, intrafemoral thrombolysis significantly improves ulcer closure rates at the 1-month intervention stage and demonstrates better outcomes during the 6.5-year follow-up. The therapy is associated with reduced cardiovascular events, especially cardiovascular death, and improvements in local skin oxygenation, peripheral neuropathy, and glycolipid metabolic profiles.

  • #endo-diabetology

Like

Save

Share